Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.79 USD | +0.47% | -3.60% | +4.70% |
May. 22 | Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target | MT |
May. 16 | Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing | MT |
Business Summary
- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.
Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Number of employees: 3,050
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Protein Sciences
74.4
%
| 832 | 75.3 % | 846 | 74.4 % | +1.61% |
Diagnostics and Genomics
25.7
%
| 275 | 24.9 % | 293 | 25.7 % | +6.46% |
Intersegment
-0.1
%
| -2 | -0.1 % | -2 | -0.1 % | +5.92% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
56.5
%
| 614 | 55.5 % | 642 | 56.5 % | +4.62% |
EMEA, excluding United Kingdom
19.4
%
| 219 | 19.8 % | 220 | 19.4 % | +0.54% |
Greater China
10.0
%
| 112 | 10.2 % | 114 | 10.0 % | +1.27% |
APAC, excluding Greater China
6.4
%
| 76 | 6.9 % | 73 | 6.4 % | -3.87% |
United Kingdom
4.4
%
| 49 | 4.4 % | 49 | 4.4 % | +1.69% |
Rest of World
3.3
%
| 35 | 3.2 % | 37 | 3.3 % | +6.44% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
James Hippel
DFI | Director of Finance/CFO | 53 | 14-03-31 |
Matthew McManus
COO | Chief Operating Officer | 55 | Jan. 07 |
David Clair
IRC | Investor Relations Contact | - | - |
Shane Bohnen
LAW | General Counsel | 49 | 19-03-02 |
Qi Cheng
PRN | Corporate Officer/Principal | - | 21-07-26 |
Brenda Everson
HRO | Human Resources Officer | - | 22-01-09 |
William Geist
PRN | Corporate Officer/Principal | 55 | 22-01-02 |
Robert Gavin
PRN | Corporate Officer/Principal | 56 | 14-11-24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02-12-31 | |
Randolph Steer
BRD | Director/Board Member | 74 | 89-12-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 17-10-25 |
John Higgins
BRD | Director/Board Member | 54 | 09-05-18 |
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
Roeland Nusse
BRD | Director/Board Member | 74 | 10-05-25 |
Julie Bushman
BRD | Director/Board Member | 63 | 20-07-30 |
Rupert Vessey
BRD | Director/Board Member | 59 | 19-06-25 |
Alpna Seth
BRD | Director/Board Member | 60 | 17-10-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 157,584,637 | 156,051,728 ( 99.03 %) | 0 | 99.03 % |
Company contact information
Bio-Techne Corp.
614 McKinley Place North East
55413-2610, Minneapolis
+612 379 8854
http://www.bio-techne.comSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.70% | 12.67B | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+24.10% | 12.27B | |
+27.41% | 12.07B | |
-8.12% | 11.21B |
- Stock Market
- Equities
- TECH Stock
- Company Bio-Techne Corporation